[HTML][HTML] Structural biology of SARS-CoV-2: open the door for novel therapies
W Yan, Y Zheng, X Zeng, B He, W Cheng - Signal Transduction and …, 2022 - nature.com
Abstract Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) is the causative
agent of the pandemic disease COVID-19, which is so far without efficacious treatment. The …
agent of the pandemic disease COVID-19, which is so far without efficacious treatment. The …
Structural insights into SARS-CoV-2 proteins
The unprecedented scale of the ongoing COVID-19 pandemic has catalyzed an intense
effort of the global scientific community to unravel different aspects of the disease in a short …
effort of the global scientific community to unravel different aspects of the disease in a short …
[HTML][HTML] Antiviral drug discovery: preparing for the next pandemic
Clinically approved antiviral drugs are currently available for only 10 of the more than 220
viruses known to infect humans. The SARS-CoV-2 outbreak has exposed the critical need …
viruses known to infect humans. The SARS-CoV-2 outbreak has exposed the critical need …
An updated review of computer‐aided drug design and its application to COVID‐19
The recent outbreak of the deadly coronavirus disease 19 (COVID‐19) pandemic poses
serious health concerns around the world. The lack of approved drugs or vaccines continues …
serious health concerns around the world. The lack of approved drugs or vaccines continues …
Targeting SARS-CoV-2 proteases and polymerase for COVID-19 treatment: state of the art and future opportunities
The newly emerged coronavirus, called SARS-CoV-2, is the causing pathogen of pandemic
COVID-19. The identification of drugs to treat COVID-19 and other coronavirus diseases is …
COVID-19. The identification of drugs to treat COVID-19 and other coronavirus diseases is …
Protease targeted COVID-19 drug discovery and its challenges: Insight into viral main protease (Mpro) and papain-like protease (PLpro) inhibitors
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) brutally perils physical and
mental health worldwide. Unavailability of effective anti-viral drug rendering global threat of …
mental health worldwide. Unavailability of effective anti-viral drug rendering global threat of …
Structure-based optimization of ML300-derived, noncovalent inhibitors targeting the severe acute respiratory syndrome coronavirus 3CL protease (SARS-CoV-2 …
Starting from the MLPCN probe compound ML300, a structure-based optimization campaign
was initiated against the recent severe acute respiratory syndrome coronavirus (SARS-CoV …
was initiated against the recent severe acute respiratory syndrome coronavirus (SARS-CoV …
[HTML][HTML] Antiviral drug discovery for the treatment of COVID-19 infections
TI Ng, I Correia, J Seagal, DA DeGoey, MR Schrimpf… - Viruses, 2022 - mdpi.com
The coronavirus disease 2019 (COVID-19) pandemic is caused by the severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2), a recently emerged human coronavirus …
respiratory syndrome coronavirus 2 (SARS-CoV-2), a recently emerged human coronavirus …
Expedited approach toward the rational design of noncovalent SARS-CoV-2 main protease inhibitors
The main protease (Mpro) of SARS-CoV-2 is a validated antiviral drug target. Several Mpro
inhibitors have been reported with potent enzymatic inhibition and cellular antiviral activity …
inhibitors have been reported with potent enzymatic inhibition and cellular antiviral activity …
[HTML][HTML] Drug repurposing strategy (DRS): Emerging approach to identify potential therapeutics for treatment of novel coronavirus infection
BM Sahoo, BVV Ravi Kumar, J Sruti… - Frontiers in Molecular …, 2021 - frontiersin.org
Drug repurposing is also termed as drug repositioning or therapeutic switching. This method
is applied to identify the novel therapeutic agents from the existing FDA approved clinically …
is applied to identify the novel therapeutic agents from the existing FDA approved clinically …